Loading...
Market
Story
London-based Vicebio Secures $100M Series B to Advance Cost-Effective Vaccines
Sep 24, 2024, 09:51 AM
Vicebio, a London-based biotech startup, has successfully raised $100 million in a Series B financing round. The funding will be used to advance its next-generation vaccine candidates into Phase 1 clinical trials. The vaccines aim to be cost-effective and target respiratory viruses such as RSV and hMPV. The financing round saw participation from investors including TCGX, G. Sachs Alternatives, Avoro, venBio, uniQuest, and Medicxi.
View original story
Similar markets
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
